AGM
CADL icon

Alpine Global Management’s Candel Therapeutics CADL Stock Holding History

Alpine Global Management’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-18,761
Closed -$116K – 206
2024
Q2 		$116K Buy
+18,761
New +$141K 0.02% 387

Other funds holding CADL

NV
Northpond Ventures Bethesda, Maryland $43.7M AUM 27.27% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
HFF
Halter Ferguson Financial Carmel, Indiana $456M AUM 49.85% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Alpine Global Management's CADL Position: Q3 2024 in Review

Alpine Global Management sold out of Candel Therapeutics (CADL) in Q3 2024, closing a stake of 18,761 shares — an estimated $116K sold.

Alpine Global Management first reported a position in CADL in Q2 2024 and held it in 1 quarter. The position peaked at $116K in Q2 2024. 52 funds tracked by Wall St. Rank hold CADL as of Q3 2024.

  • Alpine Global Management reported no remaining Candel Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Alpine Global Management sold 18,761 Candel Therapeutics shares in Q3 2024, an estimated $116K.
  • Alpine Global Management first reported a position in Candel Therapeutics in Q2 2024 and held it in 1 quarter.
  • Alpine Global Management's Candel Therapeutics position peaked at $116K in Q2 2024.
  • 52 funds tracked by Wall St. Rank held Candel Therapeutics as of Q3 2024.

Based on Alpine Global Management's 13F filing for Q3 2024, filed 14 Nov 2024.